Stanley Jordan, MD — Biomedical Watch V2

Traitements3programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
ClazakizumabThe purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.	Hypertension, Maladie rénale chronique	Phase 1/2	Immunomodulation	United States	À vérifier
ClazakizumabThe purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.	Maladie rénale chronique	Phase 2	Immunomodulation	United States, Argentina, Japan, Puerto Rico	À vérifier
ClazakizumabThe purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.	Maladie rénale chronique	Phase 1/2	Immunomodulation	United States	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Clazakizumab	Maladie rénale chronique	Phase 1/2	NCT03380962	Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant	COMPLETED
Clazakizumab	Maladie rénale chronique	Phase 2	NCT07783802	CLARITY-CRP — A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.